Tele2 Estonia boosts performance with ADVA ALM fiber monitoring solution
ADVA (FSE: ADV) today announced that Tele2 Estonia has deployed the ADVA ALM fiber monitoring solution for real-time assurance across its national network. The compact, plug-and-play device boosts operational efficiency and service availability. This helps Tele2 Estonia to improve customer experience and offer enhanced SLAs. Managed by the Ensemble Controller network management system with Ensemble Fiber Director, the solution gives Tele2 Estonia’s field forces full control over their optical infrastructure. With its simple graphical overlay, the ADVA ALM precisely pinpoints the location of fiber impairments, enabling proactive maintenance, reducing repair times and preventing network outages.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220627005471/en/
ADVA’s ALM is helping Tele2 Estonia to eliminate downtime and ensure services stay online. (Photo: Business Wire)
“With the ADVA ALM, we can offer even more value to our customers. Needing no calibration, it easily plugged into our infrastructure to instantly provide detailed info on any fiber event. Having the ability to rapidly respond to network issues and take immediate targeted action helps us ensure zero downtime and uninterrupted connectivity,” said Asse Hang, head of international sales at Tele2 Estonia. “This deployment is also central to our role as a sustainability leader. As the first communication service provider (CSP) in the Baltic region to have achieved climate neutral operations, we’re dedicated to reducing environmental impact in every aspect of our business. The ADVA ALM fiber monitoring solution enables us to dramatically decrease truck rolls, helping to further cut our carbon footprint”.
The ADVA ALM is a low-power, service-agnostic solution that offers total fiber infrastructure visibility. Requiring no active equipment at the user site, it’s now delivering comprehensive insight into the integrity and performance of Tele2 Estonia’s fiber infrastructure. The Ensemble Fiber Director provides a GIS-based, real-time graphical user interface that proactively notifies the CSP’s field forces of any fiber anomaly, enabling them to take countermeasures before problems develop and services are affected. With complete control, Tele2 Estonia is now significantly improving robustness and efficiency across its nationwide network, which is built on the ADVA FSP 3000.
“Tele2 Estonia is a CSP committed to adding value for its customers. Now it’s harnessing our ALM as part of its mission to eradicate network downtime. With round-the-clock fiber monitoring, Tele2 Estonia can initiate instant troubleshooting, helping to avoid service disruption and empowering it to offer more valuable SLAs,” commented Hartmut Müller-Leitloff, SVP of sales, EMEA at ADVA. “Uniquely compact and affordable, there really is no other fiber assurance technology on the market that delivers as much with such little investment. Our ALM is the easiest way to guarantee superior network performance, save time and money, and help tackle environmental impact.”
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
ADVA Optical Networking SE, Munich, Germany
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
t +44 1904 699 358
t +49 89 890 665 854
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
IFF Unveils Nourish Innovation Lab in Union Beach, New Jersey19.8.2022 12:55:00 CEST | Press release
IFF (NYSE:IFF) today announced the opening of its new Nourish Innovation Lab at the company’s Union Beach, New Jersey research and development center. In the state-of-the-art lab, scientists—including flavorists and food designers—will leverage tools, technologies and ingredient expertise to offer customers full product design, driving growth in the global food and beverage markets by fast forwarding innovation. “This new facility is a testament to how we pioneer innovation and drive speed to market and accessibility to our customers,” said Nicolas Mirzayantz, president of Nourish, IFF. “We will nurture an innovation project from concept to kitchen table, under one roof. Using our scientific knowhow, application excellence and full portfolio of ingredients, we’ll improve the taste and nutrition profiles of next-generation food and beverages. With our new culinary kitchen, we’re enabling technology focused on the consumer-eating experience, taking food development out of the traditional
PUMA Ambassador and European Champion Gianmarco Tamberi Talks “Only See Great”19.8.2022 11:52:00 CEST | Press release
Six years after his first gold medal, Tamberi takes back the European title and speaks about his motivation to keep performing at the highest level in a video interview with sports company PUMA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220819005125/en/ Six years after his first gold medal, Tamberi takes back the European title and speaks about his motivation to keep performing at the highest level in a video interview with sports company PUMA. (Photo: Business Wire) With the ‘Only See Great’ campaign, PUMA explores the career path of its brand ambassadors, as they talk about their own pursuit of greatness, listening to their hearts, and finding a vision that no one else can see. In the interview, Gianmarco talks about his very first successes and extraordinary performance at the Olympic Games in Tokyo. “That feeling that I had that day, that happiness I couldn’t even imagine that could exist. It’s something that was co
Kyowa Kirin Receives European Commission Approval for Use of CRYSVITA ® ▼ (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)19.8.2022 10:30:00 CEST | Press release
Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the European Commission (EC) approved CRYSVITA® (burosumab) for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed in the EU for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with fewer than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with progressive and debilitating musculoskeletal deficits,6,7 ultimately having a detr
Kapruvia ® approved in Switzerland with additional regulatory decisions expected in H2 202219.8.2022 07:00:00 CEST | Press release
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced that they have received approval for Kapruvia® from the Swiss Agency for Therapeutic Products (Swissmedic). Kapruvia® will be the first therapy available for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients. Swissmedic approval for Kapruvia® follows approvals by the U.S. Food and Drug Administration, by the European Medicines Agency, by the UK Medicines and Healthcare products Regulatory Agency, as well as by Health Canada. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220818005552/en/ “The approval of Kapruvia® in Switzerland is the next step on our journey to bring this breakthrough treatment to hemodialysis patients living with CKD-associated pruritus around the world,” said Dr. Klaus Henning Jensen, Chief Medical Officer of CSL Vifor. “There is a
European Commission Approves Celltrion Healthcare’s Vegzelma™ (CT-P16, biosimilar bevacizumab) for the Treatment of Multiple Types of Cancer19.8.2022 04:47:00 CEST | Press release
Celltrion Healthcare announced today that the European Commission (EC) has approved Vegzelma™ (CT-P16), a biosimilar bevacizumab referencing EU-approved Avastin®, for the treatment of metastatic breast cancer, non-small cell lung cancer, advanced and/or metastatic renal cell cancer, metastatic carcinoma of the colon or rectum, ovarian cancer and cervical cancer. “The European Commission’s approval of Vegzelma™ will increase access to treatment for patients living with certain types of cancer at an affordable price,” said Kevin Byoung Seo Choi, Senior Vice President and Head of Marketing Division at Celltrion Healthcare. “With proven similarities in efficacy and safety compared to the reference product Avastin®, Vegzelma™ will be available to treat some of the most commonly diagnosed cancers, which collectively affect hundreds of thousands of European patients each year.” The EC approval of Vegzelma™ follows the recommendation for marketing authorisation issued by the Committee for Medi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom